MND-2119 Clinical Pharmacology Study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210362

Enrollment

Registered

2021-10-02

Start date

2021-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult subjects

Interventions

No intervention arm MND-2119 2 g arm:MND-2119 2 g, orally, once daily after breakfast. MND-2119 4 g arm:MND-2119 4 g, orally, once daily after breakfast. EPADEL 1.8 g arm:Ethyl icosapentate 0.9 g, or

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male participants willing to participate in this clinical trial with the ability to consent and provide written consent

Exclusion criteria

Exclusion criteria: Participants with or with a history of, cardiac, hepatic, renal, respiratory, hematologic, gastrointestinal, thyroid gland, psychological, neurologic, metabolic, and electrolyte disorders that are considered by the principal (or sub-) investigator as ineligible to participate in the study

Design outcomes

Primary

Measure	Time frame
Fatty acid composition of plasma and blood cells Leukocyte-derived EPA metabolites Cytokine	—

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-3-3225-6303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026